-+ 0.00%
-+ 0.00%
-+ 0.00%
Bayer: Initiating a phase II trial of an investigational GIRK4 inhibitor in patients with atrial fibrillation.
Share
Listen to the news
Bayer: Initiating a phase II trial of an investigational GIRK4 inhibitor in patients with atrial fibrillation.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending